Last reviewed · How we verify
NCT04966676: ATLAS
Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer
Phase 2 trial testing cfDNA blood test in Non Small Cell Lung Cancer in 5 participants. Terminated before completion.
19 February 2025
Quick facts
| Lead sponsor | University Health Network, Toronto |
|---|---|
| Phase | Phase 2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 5 |
| Start date | 24 January 2022 |
| Primary completion | 19 February 2025 |
| Estimated completion | 19 February 2025 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- cfDNA blood test
- Nivolumab (nivolumab) — full drug profile →
- Ipilimumab — full drug profile →
- Platinum-based Chemotherapy — full drug profile →
Conditions studied
- Non Small Cell Lung Cancer — all drugs for Non Small Cell Lung Cancer →
Sponsor
University Health Network, Toronto
Who can join
18 and older, any sex, with Non Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this research study is to look at how effective two drugs, nivolumab and ipilimumab, are for people with non-small lung cancer that has metastasized (has spread to other parts of the body) and to see what effects these drugs have on these tumors.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy.
Sivapalan L, Murray JC, Canzoniero JV, Landon B, et al · · 2023 · cited 89× · PMID 36657818 · DOI 10.1136/jitc-2022-005924 -
Translating the evolving molecular landscape of tumors to biomarkers of response for cancer immunotherapy.
Anagnostou V, Landon BV, Medina JE, Forde P, et al · · 2022 · cited 38× · PMID 36350985 · DOI 10.1126/scitranslmed.abo3958 -
Elucidating the Heterogeneity of Immunotherapy Response and Immune-Related Toxicities by Longitudinal ctDNA and Immune Cell Compartment Tracking in Lung Cancer.
Murray JC, Sivapalan L, Hummelink K, Balan A, et al · · 2024 · cited 27× · PMID 37939140 · DOI 10.1158/1078-0432.ccr-23-1469 -
Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer treated by immune checkpoints inhibitors.
Ancel J, Dormoy V, Raby BN, Dalstein V, et al · · 2023 · cited 24× · PMID 37283751 · DOI 10.3389/fimmu.2023.1171649 -
Next-generation ctDNA-driven clinical trials in precision immuno-oncology.
Aggarwal C, Leighl NB. · · 2023 · cited 3× · PMID 36657816 · DOI 10.1136/jitc-2022-006397 -
Mutational Signature Changes in Patients With Metastatic Squamous Cell Carcinoma of the Anal Canal.
LaPelusa M, Cann C, Ciombor KK, Eng C. · · 2024 · PMID 38103030 · DOI 10.1093/oncolo/oyad326
Verify or expand the search:
- PubMed search for NCT04966676
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Non Small Cell Lung Cancer
Currently open trials in the same condition.
- NCT06951646 — ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immuno · Phase 2 · recruiting
- NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
- NCT07269782 — A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCL · Phase 2 · recruiting
- NCT07306624 — Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer · Phase 2 · recruiting
- NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting
Other University Health Network, Toronto trials
Trials by the same sponsor.
- NCT06831032 — Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response · NA · recruiting
- NCT06634056 — Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients U · Phase 2 · not yet recruiting
- NCT06836726 — Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resis · Phase 2 · not yet recruiting
- NCT07515651 — Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas · Phase 2 · not yet recruiting
- NCT07509450 — Fecal Microbiota Transplantation in Patients Undergoing Chimeric Antigen Receptor T-cell Therapy and Allogeneic Stem Cel · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04966676 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Health Network, Toronto
- Last refreshed: 8 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04966676.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing